Skip to main content

Market Overview

AzurRx BioPharma To Test Formulated Niclosamide In COVID-19-Related Gastrointestinal Infections

Share:
AzurRx BioPharma To Test Formulated Niclosamide In COVID-19-Related Gastrointestinal Infections
  • AzurRx BioPharma Inc (NASDAQ: AZRXhas initiated Phase 2 RESERVOIR trial evaluating oral formulation of micronized niclosamide (FW-1022) for the treatment of COVID-19 related gastrointestinal (GI) infections.
  • Patient enrollment is expected to begin soon, with topline data anticipated in Q1 2022.
  • The Phase 2 trial is a two-part, two-arm, placebo-controlled study examining the safety and efficacy of FW-1022.
  • This trial's two primary objectives will be to confirm the safety of niclosamide and demonstrate efficacy in clearing the SARS-CoV-2 virus from the GI tract.
  • The trial's primary efficacy measure is the rate of fecal SARS-CoV-2 virus clearance (rectal swab or stool sample), comparing the niclosamide arm to the placebo arm for up to six months.
  • Price Action: AZRX shares are trading 0.95% lower at $0.971 on the last check Tuesday.
 

Related Articles (AZRX)

View Comments and Join the Discussion!

Posted-In: Briefs Covid-19Biotech News Penny Stocks Health Care FDA General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com